Haematological aspects of obstructive sleep apnoea

Sleep Medicine Reviews

Volumn 5, Issue 3, 2001, Pages 207-221

  Eisensehr, I ^a   Noachtar, S ^a  

^a UNIVERSITY OF MUNICH   (Germany)

Author keywords

Haematocrit; Haemoconcentration; Obstructive sleep apnoea; Platelet activation; Polycythaemia; Volume regulation

Indexed keywords

ALDOSTERONE; ERYTHROPOIETIN; NATRIURETIC FACTOR; RENIN; VASOPRESSIN;

ADRENERGIC SYSTEM; BLOOD CELL COUNT; CLINICAL FEATURE; CONTROLLED STUDY; HEMATOCRIT; HEMATOLOGICAL PARAMETERS; HEMOCONCENTRATION; HUMAN; MAJOR CLINICAL STUDY; MORBIDITY; MORTALITY; PATHOPHYSIOLOGY; PLASMA VOLUME; POLYCYTHEMIA; REGULATORY MECHANISM; REVIEW; SLEEP APNEA SYNDROME; THROMBOCYTE ACTIVATION; THROMBOCYTE COUNT; THROMBOCYTE FUNCTION;

EID: 0034930894     PISSN: 10870792     EISSN: None     Source Type: Journal    
DOI: 10.1053/smrv.2001.0158     Document Type: Review

References (66)

1. Snoring as a risk factor for ischaemic heart disease and stroke in men
2. A platelet alpha granule membrane protein that is associated with the plasma membrane after activation: Characterization and subcellular localization of platelet activation-dependent granule-external membrane protein
3. Changes in the platelet membrane glycoprotein IIb-IIIa complex during platelet activation
4. Activation-induced modulation of the platelet surface expression of glycoprotein IV in vitro and in vivo
5. Downregulation of the platelet surface glycoprotein Ib-IX complex in whole blood stimulated by thrombin, adenosine diphosphate, or in vivo wound
6. Detection of activated platelets in whole blood using activation-dependent monoclonal antibodies and flow cytometry
7. Measurements of fibrinogen binding to platelets in whole blood by flow cytometry: A micromethod for the detection of platelet activation
8. Eicosanoid biosynthesis in human cardiovascular disease
9. Epinephrine induces platelet fibrinogen receptor expression, fibrinogen binding and aggregation in whole blood in the absence of other excitatory agonists
10. Epinephrine potentiates human platelet activation but is not an aggregating agent
11. Intracellular regulatory processes in platelets
12. Physiology of the autonomous nervous system as related to cardiovascular function: Implications for stress research
13. Increased platelet aggregate formation in patients with chronic airflow obstruction and hypoxemia
14. Changes in platelet function in patients with arterial hypertension
15. Evidence for an alternative mechanism of human platelet secretion involving peripheralization of secretory granules and formation of membrane-associated multivesicular structures
16. Blood platelet count and function are related to total and cardiovascular death in apparently healthy men
17. Angiographic and clinical predictors of acute closure after native vessel coronary angioplasty
18. Biochemical evidence of platelet activation in patients with unstable angina
19. High prevalence of hypertension in sleep apnea patients independent of obesity
20. Epinephrine induces platelet fibrinogen receptor expression, fibrinogen binding and aggregation in whole blood in the absence of other excitatory agonists
21. Urinary catecholamines before and after tracheostomy in patients with obstructive sleep apnea and hypertension
22. Morning increase of whole blood viscosity in obstructive sleep apnea syndrome
23. New insights into the therapy and pathophysiology of patients with obstructive sleep apnoea syndrome
24. Platelet function and fibrinolytic activity in hypertensive and normotensive sleep apnea patients
25. Compensatory excretion of prostacyclin and thromboxane metabolites in obstructive sleep apnea syndrome
26. Urinary excretion of prostanoids during sleep in obstructive sleep apnoea patients
27. Spontaneous platelet activation and aggregation during obstructive sleep apnea and its response to therapy with nasal continuous positive airway pressure. A preliminary investigation
28. Platelet activation, epinephrine, and blood pressure in obstructive sleep apnea syndrome
29. Effects on platelet aggregation and fibrinolytic activity during upright posture and exercise in healthy men
30. 2-adrenoceptor interaction
31. Peritubular cells are the site of erythropoietin synthesis in murine hypoxic kidney
32. Neurologic complications of polycythemia
33. The influence of hemorheology on the practice of clinical medicine
34. Secondary polycythaemia associated with nocturnal apnoea - A relationship not mediated by erythropoietin?
35. Intermittent hypoxia in patients with unexplained polycythaemia
36. Oxygen desaturation in apparent and relative polycythaemia
37. Erythropoietin response to acute normobaric hypoxia in humans
38. Hematocrit levels in sleep apnea
39. Effect of nasal CPAP treatment on plasma volume, aldosterone and 24-h blood pressure in obstructive sleep apnoea
40. Auswirkungen einer nCPAP therapie auf das blutbild bei patienten mit einer obstruktiven schlafapnoe
41. Decrease in hematocrit with continuous positive airway pressure treatment in obstructive sleep apnoea patients
42. Effects of NCPAP therapy on fibrinogen levels in obstructive sleep apnea syndrome
43. Overnight decrease in hematocrit after nasal CPAP treatment in OSA patients
44. Erythropoietin concentrations in obstructive sleep apnoea
45. Diurnal variations in serum erythropoietin levels in healthy subjects and sleep apnea patients
46. Urinary uric acid: Creatinine ratio, serum erythropoietin, and blood 2,3-diphosphoglycerate in patients with obstructive sleep apnea
47. Humoral correlates of sleep apnoea: Erythropoietin and hypoxemia
48. Erythropoietin response in subjects with obstructive sleep apnea
49. Erythropoietin levels with treatment of obstructive sleep apnea
50. Regulation of plasma volume during obstructive sleep apnoea
51. Regulation of blood volume-implications for cardiovascular pathophysiology in sleep apnoea
52. Diurnal and nocturnal diuresis and natriuresis in obstructive sleep apnea. Effects of nasal continuous positive airway pressure therapy
53. Atrial natriuretic peptide release during sleep in patients with obstructive sleep apnoea before and during treatment with nasal continuous positive airway pressure
54. Effects of treatment with continuous positive airway pressure on atrial natriuretic peptide and arginine vasopressin release during sleep in patients with obstructive sleep apnoea
55. Urinary excretion of guanosine 3′:5′-cyclic monophosphate during sleep in obstructive sleep apnoea patients with and without nasal continuous positive airway pressure treatment
56. Changes of circulating atrial natriuretic peptide and antidiuretic hormone in obstructive sleep apnea syndrome
57. Einfluß der schlafapnoe auf volumenregulierende hormonsysteme hinweise für komplexe störungen der volumenregulation
58. Plasma levels of atrial natriuretic factor in moderate to severe obstructive sleep apnea syndrome
59. Atrial natriuretic peptide and catecholamines in obstructive sleep apnea syndrome
60. Secretion of atrial natriuretic peptide from the heart in man
61. Lack of effect of an inspiratory threshold load on plasma atrial natriuretic peptide levels
62. Abnormal diurnal variation in salt and water excretion in patients with obstructive sleep apnoea
63. Renal function in patients with obstructive sleep apnoea-effects of nasal continuous positive airways pressure
64. Renal function and sleep apnea syndromes
65. Obstructive sleep apnea treatment: Peripheral and central effects on plasma renin activity and aldosterone
66. PADGEM protein: A receptor that mediates the interaction of activated platelets with neutrophils and monocytes